ABEONA THERAPEUTICS INC. Increase (Decrease) in Accounts Receivable
ABEONA THERAPEUTICS INC. (ABEO) reported Increase (Decrease) in Accounts Receivable of $3.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $3.19M.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $53.00K.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts receivable for the quarter ending 2022-12-31 was $0.00.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts receivable for the quarter ending 2022-09-30 was -$1.00M.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts receivable for fiscal 2025 was $6.15M.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts receivable for fiscal 2022 was -$3.00M, a 200.00% decline from fiscal 2021.
- ABEONA THERAPEUTICS INC. increase (decrease) in accounts receivable for fiscal 2021 was $3.00M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.25M 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | $53.00K 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $6.15M 10-K · filed 2026-03-17 | |||
| 2023-06-30 | $3.50M 10-Q · filed 2024-08-12 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$1.00M derived: sum of 2 quarters · filed 2024-03-18 | $0.00 derived: sum of 3 quarters · filed 2024-03-18 | -$3.00M 10-K · filed 2024-03-18 |
| 2022-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | -$3.00M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$2.00M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$3.00M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $3.00M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |